Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
quite a volume surge right out of the gates today, but no real movement though.
.143 with heavy volume. maybe it will get noticed tomorrow...
seems to have pierced resistance @.135. not sure what's driving this, but its steadily melting up.
edit: based on historical volume, it doesn't look like there is any major resistance after .16 ...
Aug 16, 2016 - GH Solutions Inc Announces New KOIOS Product to Be Distributed by Europa
GREENWOOD VILLAGE, CO -- (Marketwired) -- 08/16/16 -- GH Solutions (OTC: GRSU), a company focused on creating functional operating divisions within the hemp industry, today announced the Company's new KOIOS Raspberry Wonder with Hemp beverage will soon to be released and will be distributed by Europa, the nation's largest distributor of Sports Nutrition Products.
"KOIOS currently has a partnership with Europa on their existing beverage as well as their supplement," stated John George Michak III , COO of GH Solutions Inc. "Europa recently merged with Lone Start Distribution, making it the largest distributor of Sports Nutrition products in the nation," he continued. "This relationship represents the potential of slotting our hemp-based beverage in over 50,000 stores that KOIOS already markets within. We believe that will make this a very swift and successful launch," he concluded.
KOIOS currently distributes their products in: Max Muscle Nation Wide, Nutrition Warehouse, Nutrition Zones, Power Nutrition, Hi Health (45 Locations), Gold's Gym, Powerhouse Gym , Smoothie Kings (nationwide), Nutri Shop, Ultimate Sport Nutrition, Nutrition Depot, Anytime Fitness , Complete Nutrition and many more.
"Europa is the largest distributor in the nation in the Sports Nutrition category and we are honored to work with them," stated Chris Miller , President of KOIOS. "We anticipate, through Europa's network, to be in well over four thousand supplement stores across the nation in the next twenty-two months, including international locations," he continued. "The work we have done with our current ready-to-drink product has set the tone and opened thousands of doors across the country who are eagerly awaiting our newest iteration, Raspberry Wonder with Hemp. We know this new flavor and the addition of hemp to our existing formula will allow us to break records," he concluded.
GH Solutions expects to issue updates on additional distribution partnerships in the very near future.
About GH Solutions, Inc.
GH Solutions, Inc. is a science-based company focused on operating divisions within the burgeoning hemp industry. GH Solutions brings a patented technological advancement to the nutraceutical, functional beverage, and health food markets. As the exclusive licensee of US Patent #6080401 for hemp/cannabis based applications, the Company is the sole source of formulations that offer the benefits of botanicals like hemp seed oil with the health and wellness effects of probiotics. GH Solutions encourages all current and prospective shareholders to visit our website at: www.ghsolutionsinc.com or Greenhouse's Facebook page at https://m.facebook.com/Greenhousesolutionsinc
About KOIOS
KOIOS LLC creators began developing their own nootropic formulas to combat their ADHD and to eliminate harmful stimulants out of their lives. After several years of research, testing and development with an INC 5000 lab, they formulated KOIOS. Each ingredient has more than a decade of research behind it from some of the largest medical institutions in the world. KOIOS combined 11 of the most potent nootropics, to give you a finely tuned, high performance brain enhancement supplement. Not only are the short-term results of KOIOS staggering, but each ingredient in our formula has been shown, scientifically, to have long lasting positive effects on the brain. KOIOS encourages people to visit their website to learn more: http://www.mentaltitan.com
SEC Disclaimer This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Greenhouse Solutions' ("the Company's") business plan. The launch of the new product through EUROPA should not be construed as an indication in any way whatsoever of the future value of the Company's common stock or its present or future financial condition. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov; statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
Contact:
GH Solutions Inc.
info@ghsolutionsinc.com
Ghsolutionsinc.com
1-877-895-5647
Source: Greenhouse Solutions, Inc.
still creeping up, little by little...
volume spike yesterday, and a little movement today...
seem to be approaching the 1 year mark for the "727 assignment to creditors filing" not sure how that works though
wonder if the bid uptick and disappearance of the 100K+ seller(s) will hold...
SANTA CLARA, Calif. --(BUSINESS WIRE)-- Iris Biotechnologies announces that the Japanese Patent Office has issued a notice of allowance of its Artificial Intelligence System for Genetic Analysis to be granted as a patent. This follows the issuance of a family of patents in the US, EU, Canada , Hong Kong , Australia, and New Zealand .
A critical mass of scientific knowledge, instrumentation and affordable computing power is at hand, yet a critical piece has been missing which Iris is now able to provide: smart integration of genomic, proteomic, lifestyle, family history and environmental information. Iris is poised to play a leading role in answering the unmet needs of a multi-billion-dollar market.
"Compared to when Iris Biotechnologies common stock (IRSB) was trading at $4.50 per share, the Company now has more patents worldwide and is planning to launch the first Iris Wellness Labs this summer," said Iris CEO Simon Chin . To read more about Iris Wellness services, please visit ir.irisbiotech.com under Quick Links.
About Iris Biotechnologies Inc.
Iris Biotechnologies Inc. (OTC MKTS: IRSB), unlike other life sciences companies, focuses on providing accurate, affordable precision healthcare through comprehensive analysis of the whole person inside and out. Iris offers the best approach to the treatment of cancer and other diseases through incorporating DNA, RNA and protein analysis with a patient's medical records, family medical history, life style and environmental exposures. Iris enables personalized, cost-effective healthcare and is the future of precision medicine.
Forward-looking Statements
Statements in this presentation about the Company's expectations, applications of its technology, markets, launch of tests and other statements that are not historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on management's current beliefs, assumptions, estimates and projections. Actual results may differ materially from those projected in the forward-looking statements for various reasons, including risks associated with product and test development, test transfer to contracting labs, government regulation, market acceptance, limited commercial experience, dependence on key personnel, obtaining financing and other factors discussed in the Company's periodic reports filed with the Securities and Exchange Commission .
View source version on businesswire.com: http://www.businesswire.com/news/home/20160613005173/en/
CONTACT: Iris Biotechnologies Inc.
Simon Chin , 408-806-7149
President and CEO
simonchin@irisbiotech.com
Source: Iris Biotechnologies Inc.
CDEL pushing the bid all of a sudden...
SANTA CLARA, CA -- (Marketwired) -- 05/23/16 -- Iris BioTechnologies Inc. (OTC PINK: IRSB) announces its BioWindowsâ„¢ 3-Risk Scores System for Multi-Omic Analysis, which will be offered through its subsidiary, Iris Wellness Labs . The System performs intricate correlations, while presenting results in a user-friendly visual format, allowing physicians and patients to understand and act on complex molecular information.
Simon Chin , Iris BioTechnologies President and CEO, stated, "The 3-Risk system can have an immediate impact on saving and improving the quality of life for many people. Through decades of dedicated hard work, Iris makes things easier for its customers."
With Iris's 3-Riskâ„¢ Analysis System, a patient can see his or her risk of disease, mortality and recurrence for a variety of diseases using a combination of genomics, proteomics, and other analytics. This offers an opportunity for physicians and patients to discuss medical treatment, disease-free survival and overall survival in a more informed context.
Each person's unique DNA is important, but life involves a continuous conversation between a person's DNA and its molecular world. To turn the vast pool of molecular activity into clinically useful information, one must look at the whole picture: DNA sequence, gene expression, protein expression, lifestyle and environment.
In analyzing DNA itself, it is important to understand single molecule substitutions, insertions and deletions, copy number variations, and chromosome translocations. Getting one's DNA sequenced is just the beginning. What is more important is to understand the significance of the changes in one's DNA.
Using next-generation sequencing (NGS) technology, one's DNA variances can be examined for personal medical risk association. Variances may be sorted into different categories such as known disease-associated mutation, predicted disease-associated mutation, variant of unknown significance, and others. Knowing the right categorization and seeing risk association easily has the potential to inform and save lives.
NGS can also be used to determine gene expression. In the Iris 3-Risk System, gene expression and protein expression information, obtained by using technologies that exist today, are incorporated into the analysis process.
Iris's approach involves complex Big Data analytics, genomics, and proteomics, in relation to wellness and disease progression. The company's technology is based upon the understanding of medicine, biology, chemistry, nanotechnology, semiconductor manufacturing, and microfluidics. Iris has created intellectual properties in methods, devices, and systems.
Cancer Treatment : Getting the Right Actionable Information
President Richard Nixon declared the "War on Cancer" more than 40 years ago. While progress has been made in some areas, cancer remains the emperor of all maladies. With the Iris 3-Risk Scores System, Iris can overcome the problem of getting too little information or being seized by information overload. Getting the right information at the right time can be a matter of life and death.
A picture is worth a thousand words. To see a sample image of part of the Iris BioWindows 3-Risks System, please look at the "Investor Presentation" posted on the Iris website at ir.irisbiotech.com under Quick Links. Cancer, human genomes, and the Iris 3-Risk System are complex and cannot be adequately described in a press release. To better understand how they are related, please read, "Understanding the Genome" under Quick Links.
In the Iris BioWindows 3-Risks System, the smart phone will be the primary medical interface between Iris, consumers, patients, and the medical community. We also enable computer access to secure, cloud-based, vital wellness and medical information.
About Iris BioTechnologies Inc.
Iris BioTechnologies Inc. (OTC PINK: IRSB) is a life sciences company focused on providing accurate, affordable precision healthcare. Unlike other companies, Iris looks at the whole picture and is the future of medicine. Iris offers the best approach to the treatment of cancer and other diseases through actionable integration of molecular profiling in the clinical decision-making process. In the treatment of cancer, Iris can achieve precision analysis of chemotherapy effectiveness as well as risk of recurrence. Iris accomplishes this by incorporating DNA, RNA and protein analysis with a patient's medical records, family medical history, life style and environmental exposures. Iris enables personal precision healthcare by matching patient to targeted treatments, and in some cases, including therapies in clinical trials.
The Iris Nano-Biochipâ„¢ product pipeline includes: CancerChipâ„¢, Integrated Blood Test, NeuroChipâ„¢ (Alzheimer's and Parkinson diseases), MetabolicChipâ„¢ (Diabetes), CardioChipâ„¢, and Chips for veterinary, agricultural, environmental, and other applications. The Iris BioWindowsâ„¢ artificial intelligence system provides big data and analysis for clinical applications, drug development, and stem cell research.
Forward-looking Statements
Statements in this presentation about the Company's expectations, applications of its technology, markets, launch of tests and other statements that are not historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on management's current beliefs, assumptions, estimates and projections. Actual results may differ materially from those projected in the forward-looking statements for various reasons, including risks associated with product and test development, test transfer to contracting labs, government regulation, market acceptance, limited commercial experience, dependence on key personnel, obtaining financing and other factors discussed in the Company's periodic reports filed with the Securities and Exchange Commission .
For more information on Iris BioTechnologies , please visit Iris on Facebook (https://www.facebook.com/irisbiotech), Twitter (https://twitter.com/irisbiotech), and the Iris corporate website (www.irisbiotech.com).
Iris BioTechnologies Inc.Simon Chin408-806-7149President and CEOsimonchin@irisbiotech.com
Source: Iris BioTechnologies Inc.
hmm, interesting. a bit of a change in direction today....
per the 10-k, "On March 17, 2016, in preparation for our multiple product launches, our board of directors unanimously approved the increase of our authorized shares..."
don't blame anyone from reacting to this, and if i wasn't holding freebies from the bottom bounce, i might do the same.
after another seemingly random bout of volatility, the bid appears to be slowly ticking up again... back to .23x.40
a little rumbling on some after hours news.
think they have finished diluting Vista's 5M from 2/3?
ask uptick, now .30x.53. NITE must have dozed off again (up @1.00 now)
agreed on all fronts
heh, then NITE woke up and put 5k@.40. a nice little eow paint nonetheless.
3 news articles posted yesterday. http://www.iris-biotech.de/news/. they are all highly technical like the last round dated on 12/02/2016. too bad there isn't any volume like last time.
so why file 2 sc-13's for 6.5M shares, if they just won a presumably favorable settlement? CDEL seems to be eager to convert them.
down to .32x.35 (CANT x NITE)
NITE now leading on both sides, .30 x .40. maybe some volume will finally return.
another little uptick on the bid. CANT now leading with 10k@.26.
spread coming in a little, with the bid coming up...
.63?? whacky gap, but still...
might be a little wishful thinking, but it sorta looks like the bid has been slowly solidifying over the past week or so.
another form 4 with 1.38M/$83k of salary paid in stock.
i agree its not a major one, but i think it does say a little something. i mean, who knows what Chin's time is worth, but at face value, it seems that he's working for shares only. not a really compelling case by itself though.
edit: and thank you for the correction on the price. .047, not .07.
also true. 2.6M @.07 ($136k) is a much bigger endorsement, just at a much lower price.
its better than selling shares, but a $900 purchase isn't a major endorsement.
safe to say this one is rather volatile. i hope its worth holding.
then whacked down to .35 :(
spread is really compressed now. kinda odd.
only showing 3600 shares on the ask b/t .57 and 1.78?
so after a little more reading, it appears that this was trading >$2.00 before they ran into 2 snafu's (and before their patents were granted)
- Hanson McClain Filed False Reports With the Security and Exchange Commission Regarding Iris BioTechnologies - http://www.reuters.com/article/2015/03/30/idUSnCCN1Dxctm+1d0+MKW20150330
- Iris BioTechnologies Inc. Reports on Legal Proceedings Involving Heller Ehrman LLP - http://www.reuters.com/article/2015/11/25/idUSnMKW9flmta+1c0+MKW20151125
CDEL and ETRF now upticking. wow.
interesting. ETRF now showing a bid of 200k @.38....
edit: - oops, d4ward already saw that!
hmmm, so after checking their site, it looks like they posted 3 updates yesterday, all relating to the "building blocks" that were utilized in the study that was published in Nature.com (link back). These "building blocks" were used to produce a new variation of a chemotherapeutic drug that, compared to the previous version, "led to increased therapeutic activity of the drug in vivo" by having "induced tumor regression". In addition, the new variation (NT4-paclitaxel) "...is very hydrophilic, which may improve its pharmacokinetic profile and allow the use of less toxic dilution buffers, further decreasing its general chemotherapic toxicity."
- 2015-12-02Canalin and Canavanine : New Fmoc building blocks for novel peptides and protein analogs - http://www.iris-biotech.de/news/canalin-and-canavanine-new-fmoc-building-blocks-for-novel-peptides-and-protein-analogs
- Click Chemistry Tools: Propargyl Amino Acids - http://www.iris-biotech.de/news/click-chemistry-tools-propargyl-amino-acids
- Siderophore Building Block: New Hydroxamate-Ornithine for Fmoc/tBu SPPS - http://www.iris-biotech.de/news/siderophore-building-block-new-hydroxamate-ornithine-for-fmoc-tbu-spps
looks like there should be another patent granted on December 9, 2015, per this pr.